In addition, CTLA4-Ig treatment, in association with traditional DMARDs, significantly reduces the humoral response to the pandemic 2009 influenza A/H1N1 vaccine (33, 37) and to the pneumococcal conjugate vaccine in RA patients (38). The gene discussed is CTLA4; the disease is rheumatoid arthritis.